VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vanda Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.09+0.06 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
Vanda Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fanapt | $130.01M | $123.32M | $117.30M | $110.73M | $103.41M | $97.26M | $94.30M | $90.25M | $87.64M | $88.57M | $90.87M | $92.66M | 60.3% | +25.7% |
| HETLIOZ net product sales | $55.89M | $66.51M | $71.43M | $75.09M | $74.98M | $77.49M | $76.68M | $77.70M | $77.33M | $80.60M | $100.17M | $119.20M | 25.9% | -25.5% |
| PONVORY net product sales | $28.79M | $27.96M | $27.37M | $26.26M | $25.08M | $26.59M | $27.80M | $22.91M | $17.05M | $8.43M | $1.60M | – | 13.3% | +14.8% |
By region
From the segment and revenue-disaggregation notes of Vanda Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.